Drug Eluting Balloon Market Size by Product Type, Drug Type, Technology, Application, End User, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2034
Overview
The Drug Eluting Balloon Market was valued at USD 1.26 Bn in 2025, and total global Drug Eluting Balloon Market revenue is expected to grow at a CAGR of 8.0% and reach nearly USD 2.52 Bn from 2026-2034, driven by cardiovascular cases, minimally invasive, coating tech.
Drug Eluting Balloons (DEB) are conventional semi-compliant angioplasty balloons coated with an anti-proliferative drug, which is released into vessel wall during inflation of the balloon, generally at nominal pressures with a precise minimal inflation time. Drug eluting balloon plays an important role in modern healthcare, as it delivers medication and prevents neointimal hyperplasia.
Drug Eluting Balloon Market Size,Share and Growth Analysis
To know about the Research Methodology:-Request Free Sample Report
Increasing occurrence of coronary artery diseases among people across the globe is a key factor expected to drive the growth of the global market over the forecast period. According to the World Health Organization (WHO), about 17.9 Mn people die, every year caused by coronary heart disease across the globe. Besides, increasing the prevalence of diabetes is another factor expected to further fuel the growth of the market over the forecast period. For instance, according to WHO, in October 2021 reported over 1.6 Mn deaths are registered, which are caused by diabetes across globe.
Furthermore, rising manufacturer’s inclination towards acquisition strategies to develop innovative products and expand their product portfolio is another factor expected to boost the growth of the market over the forecast period. Also, the presence of major players operating in the market, such as Medtronic, Inc. and Boston Scientific Corporation and increasing R&D activities for drug eluting balloon is another factor, expected to boost the growth of the market in a certain extent.
However, adverse effects such as lumen enlargement and coronary artery lesions are expected to restrain the growth of the global market over the forecast period. For instance, in May 2021, Abbott Laboratory recalled three balloon catheters due to problems faced while removing balloon sheath, which caused 19 incidences of injury and 1 death.
Drug Eluting Balloon Market Segment Analysis
Based on technology, the drug-eluting balloon market is segmented into Paccocath, FreePac, TransPax, EnduraCoat, and others. Among these, Paccocath technology dominated due to its superior drug delivery efficiency and proven clinical outcomes in treating peripheral and coronary artery diseases. FreePac and TransPax technologies are gaining traction owing to their enhanced coating methods that ensure uniform drug release and reduced restenosis rates. EnduraCoat is known for its durability and controlled drug release, making it suitable for complex cases.
Based on end-user, the drug eluting balloon market is segmented into hospitals & ambulatory surgery centers, cath laboratories, specialty clinics, and others. Hospitals and ambulatory surgery centers hold the largest market share due to the growing number of cardiovascular procedures and availability of advanced infrastructure. Cath laboratories are increasingly adopting drug eluting balloons because of their minimally invasive nature and precise treatment delivery. Specialty clinics cater to outpatient care and are expanding due to rising demand for faster, cost-effective interventions.
According to the product type segments, the peripheral drug eluting balloon segment is expected to dominate in the market in terms of revenue over the forecast period, also on account of increasing use of drug eluting balloon for treatment of peripheral artery diseases.
Region-wise, the market in North America is expected to leading in the global market in terms of revenue over the forecast period, thanks to the increasing prevalence of cardiovascular diseases and obesity across several countries in the region over the forecast period.
The objective of the report is to present a comprehensive analysis of the Global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by Application. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by Application on the market have been presented in the report.
External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global market dynamics, structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by Type, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Drug Eluting Balloon Market make the report investor’s guide.
Drug Eluting Balloon Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 27 February 2025 | Teleflex Incorporated | Teleflex entered into a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK for approximately €760 million, incorporating key drug-coated balloon devices like the Passeo-18 Lux Peripheral DCB. | The acquisition significantly accelerates Teleflex's global expansion into the high-growth catheterization lab and peripheral vascular intervention markets. |
| 30 April 2025 | iVascular | iVascular launched its market-tailored Luminor 18 RX drug-coated balloon in Japan following approval from the Ministry of Health, Labour and Welfare (MHLW). | The commercial rollout in partnership with Medico's Hirata expands access to advanced peripheral rapid-exchange DCB therapy across Japanese healthcare facilities. |
| 19 May 2025 | Cordis | Cordis initiated the SELUTION Global Coronary Registry, a prospective study enrolling up to 10,000 patients worldwide to track long-term clinical outcomes of the SELUTION SLR Drug-Eluting Balloon. | The registry establishes an extensive real-world evidence base evaluating the 5-year efficacy and safety of sustained sirolimus delivery without permanent metallic scaffolding. |
| 27 October 2025 | Orchestra BioMed | Orchestra BioMed enrolled the first patients in its Virtue Trial U.S. pivotal IDE study evaluating the non-coated Virtue Sirolimus AngioInfusion Balloon head-to-head against paclitaxel-coated balloons. | The pivotal trial drives clinical progress toward potential FDA market approval for a novel liquid sirolimus-eluting angioplasty delivery system. |
Drug Eluting Balloon Market Scope: Inquire before buying
| Global Drug Eluting Balloon Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 1.26 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 8.0% | Market Size in 2034: | USD 2.52 Bn. |
| Segments Covered: | by Product Type | Coronary Drug-Eluting Balloons Peripheral Drug-Eluting Balloons Others |
|
| by Drug Type | Paclitaxel Sirolimus Others |
||
| by Technology | Paccocath FreePac TransPax EnduraCoat Others |
||
| by Application | Coronary Artery Disease (CAD) Peripheral Artery Disease (PAD) Others |
||
| by End User | Hospitals & Ambulatory Surgery Centers Cath Laboratories Specialty Clinics Others |
||
Drug Eluting Balloon Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Drug Eluting Balloon Market, Key players are:
1. Medtronic, Inc.
2. Becton, Dickinson and Company
3. Boston Scientific Corporation
4. Cook Medical Incorporated
5. Braun Melsungen AG
6. Koninklijke Philips N.V.
7. Opto Circuits (India) Limited
8. Terumo Corporation
9. Surmodics, Inc.
10. Biotronik, Inc.
11. Concept Medical Inc.
12. BIOTRONIK SE & Co. KG
13. Innvolution Healthcare Pvt. Ltd.
14. Medtronic plc
15. Eurocor GmbH
16. C.R. Bard
17. Aachen Resonance GmbH
Frequently Asked Questions:
1. Which region has the largest share in Global Drug Eluting Balloon Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Drug Eluting Balloon Market?
Ans: The Global Drug Eluting Balloon Market is growing at a CAGR of 8.0% during forecasting period 2026-2034.
3. What is scope of the Global Drug Eluting Balloon market report?
Ans: Global Drug Eluting Balloon Market report helps with the PESTEL, PORTER, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Drug Eluting Balloon market?
Ans: The important key players in the Global Drug Eluting Balloon Market are – Medtronic, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Cook Medical Incorporated, Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., Biotronik, Inc., Concept Medical Inc., BIOTRONIK SE & Co. KG, Innvolution Healthcare Pvt. Ltd., Medtronic plc, Eurocor GmbH, C.R. Bard, and Aachen Resonance GmbH.
5. What is the study period of this market?
Ans: The Global Drug Eluting Balloon Market is studied from 2020 to 2034.